share_log

Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock

Benzinga ·  00:00

In the preceding three months, 4 analysts have released ratings for Entrada Therapeutics (NASDAQ:TRDA), presenting a wide array of perspectives from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings22000
Last 30D11000
1M Ago00000
2M Ago00000
3M Ago11000

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.75, a high estimate of $28.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 5.81% from the previous average price target of $21.50.

bigjpg

Exploring Analyst...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment